Is It the End or Beginning of Headaches? New Drug Class Developed to Treat Migraines 

Our report provides insight on this new therapeutic class and suggests strategies for managing it

epharm_clinical_article_hiv new drugs pop_18-2159_cover graphic_borderA new class of medications known as calcitonin gene-related peptide (CGRP) inhibitors are being developed explicitly for the prevention of migraines, with one drug recently receiving Food and Drug Administration (FDA) approval. While migraines affect approximately 14% of adults in the United States, up to this point there were no medications developed specifically to prevent their occurrence. What now? 

Download our Perspective on the Rx Pipeline report to learn more about:

  • The status of development of these novel medications
  • How we will support patients using these new drugs
  • Utilization management strategies to consider to manage costs associated with these new drugs

EnvisionPharmacies is committed to helping payers understand the impact of this new therapeutic class and supporting patients who start taking CGRP inhibitors. For more information, visit envisionpharmacies.com.

DOWNLOAD OUR REPORT TO LEARN HOW CGRP INHIBITORS MAY
IMPACT YOU.